Patents by Inventor Craig Lindsley

Craig Lindsley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240109564
    Abstract: A method is provided that can include activating at least two wireless communication channels in parallel, between a first wireless transceiver and a second wireless transceiver. Each of the at least two wireless communication channels can operate at a different radio carrier frequency, and the first wireless transceiver may be part of a first vehicle. The method can also include transmitting, by the first wireless transceiver, common information in parallel on the at least two wireless communication channels to the second wireless transceiver and deactivating the at least two wireless communication channels.
    Type: Application
    Filed: December 12, 2023
    Publication date: April 4, 2024
    Inventors: Padam Dhoj Swar, Carl L. Haas, Danial Rice, Rebecca W. Dreasher, Adam Hausmann, Matthew Steven Vrba, Edward J. Kuchar, James Lucas, Andrew Ryan Staats, Jerrid D. Chapman, Jeffrey D. Kernwein, Janmejay Tripathy, Stephen Craven, Tania Lindsley, Derek K. Woo, Ann K. Grimm, Scott Sollars, Phillip A. Burgart, James Allen Oswald, Shannon K. Struttmann, Stuart J. Barr, Keith Smith, Francois P. Pretorius, Craig K. Green, Kendrick Gawne, Irwin Morris, Joseph W. Gorman, Srivallidevi Muthusami, Mahesh Babu Natarajan, Jeremiah Dirnberger, Adam Franco
  • Patent number: 8822684
    Abstract: The presently-disclosed subject matter relates to compounds of the formula: and methods for use thereof. The presently-disclosed subject matter relates methods of selectively differentiating a stem cell, and methods of screening for compounds useful for enhancing terminal differentiation of committed cardiac progenitor cells.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: September 2, 2014
    Assignee: Vanderbilt University
    Inventors: Charles C. Hong, Corey R. Hopkins, Antonis K. Hatzopoulos, Craig Lindsley, Jijun Hao
  • Publication number: 20130197027
    Abstract: In one aspect, the invention relates to compounds which are useful as allosteric or bitopic agonists of the M1 muscarinic receptor; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurodegenerative diseases, including Alzheimer's Disease. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: March 10, 2011
    Publication date: August 1, 2013
    Inventors: Craig Lindsley, P. Jeffrey Conn, Colleen M. Niswender, Michael R. Wood, Brian Chauder, Evan P. Lebois
  • Patent number: 8389545
    Abstract: The present invention is directed to quinolone compounds of general formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, pain or sleep disorders, and to novel M1 receptor positive allosteric modulator compounds of formulae (II) to (VIII). The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases in which the M1 receptor is involved.
    Type: Grant
    Filed: December 4, 2006
    Date of Patent: March 5, 2013
    Assignee: Merck, Sharp & Dohme, Corp.
    Inventors: William D. Shipe, Craig Lindsley, David Hallett
  • Patent number: 8178667
    Abstract: The present invention is directed to benzyl-substituted quinolone compounds of general formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of diseases in which the M1 receptor is involved.
    Type: Grant
    Filed: June 27, 2007
    Date of Patent: May 15, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Craig Lindsley, William D. Shipe, Feng Yang, Jaime Lynn Bunda
  • Publication number: 20100317692
    Abstract: The present invention is directed to quinolone compounds of general formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, pain or sleep disorders, and to novel M1 receptor positive allosteric modulator compounds of formulae (II) to (VIII). The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases in which the M1 receptor is involved.
    Type: Application
    Filed: February 6, 2006
    Publication date: December 16, 2010
    Inventors: William D. Shipe, Craig Lindsley, David Hallett
  • Publication number: 20100099673
    Abstract: The present invention relates to compounds represented by Formula (I): and pharmaceutically acceptable salts thereof. The present invention also provides pharmaceutical compositions comprising the instant compounds. This invention further provides methods to treat and prevent pain, respiratory and non-respiratory diseases.
    Type: Application
    Filed: January 11, 2008
    Publication date: April 22, 2010
    Inventors: Mark T. Bilodeau, Nathan R. Kett, Craig Lindsley, Peter J. Manley, Jeffrey Y. Melamed, Daniel Vincent Paone, B. Wesley Trotter, Zhicai Wu
  • Publication number: 20100009962
    Abstract: The present invention is directed to benzyl-substituted quinolone compounds of general formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of diseases in which the M1 receptor is involved.
    Type: Application
    Filed: June 27, 2007
    Publication date: January 14, 2010
    Inventors: Craig Lindsley, William D. Shipe, Feng Yang, Jaime Lynn Bunda
  • Publication number: 20090118200
    Abstract: The present invention is directed to proline bis-amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: May 22, 2006
    Publication date: May 7, 2009
    Inventors: Jeffrey M. Bergman, Paul J. Coleman, Christopher D. Cox, George D. Hartman, Craig Lindsley, Swati Pal Mercer, Anthony J. Roecker, David B. Whitman
  • Publication number: 20080021010
    Abstract: The present invention is directed to azetidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.
    Type: Application
    Filed: April 25, 2005
    Publication date: January 24, 2008
    Inventors: Craig Lindsley, David Hallett, Scott Wolkenberg
  • Publication number: 20080015212
    Abstract: The instant invention provides for canthine analogs that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.
    Type: Application
    Filed: November 28, 2005
    Publication date: January 17, 2008
    Inventors: Stanley Barnett, Michael Bogusky, William Leister, Craig Lindsley
  • Publication number: 20080009507
    Abstract: The instant invention provides for compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.
    Type: Application
    Filed: February 10, 2006
    Publication date: January 10, 2008
    Inventors: Nicholas Cosford, Mark Layton, Jun Liang, Craig Lindsley, Philip Sanderson, Zhijian Zhao
  • Publication number: 20080008708
    Abstract: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises an indole-sulfonamide moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.
    Type: Application
    Filed: August 7, 2007
    Publication date: January 10, 2008
    Inventors: Christopher Dinsmore, Douglas Beshore, Jeffrey Bergman, Craig Lindsley
  • Publication number: 20080004259
    Abstract: The instant invention provides for compounds which comprise substituted indolyl indazoles that inhibit CHK1 activity. The instant compounds provide a novel mechanism of action with unexpected advantageous properties; such unexpected advantageous properties may include increased cellular potency/solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity and so on. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.
    Type: Application
    Filed: February 3, 2006
    Publication date: January 3, 2008
    Inventors: Kenneth Arrington, Mark Fraley, Robert Garbaccio, Shaei Huang, Craig Lindsley, Justin Steen, Feng Yang
  • Publication number: 20070254880
    Abstract: The present invention is directed to pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.
    Type: Application
    Filed: March 23, 2005
    Publication date: November 1, 2007
    Inventors: Wesley Blackaby, Mark Duggan, David Hallett, George Hartman, Andrew Jennings, William Leister, Richard Lewis, Craig Lindsley, Elizabeth Naylor, Leslie Street, Yi Wang, David Wisnoski, Scott Wolkenberg, Zhijian Zhao
  • Publication number: 20070249606
    Abstract: The present invention is directed to morpholinyl piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.
    Type: Application
    Filed: April 29, 2005
    Publication date: October 25, 2007
    Inventors: Craig Lindsley, Scott Wolkenberg, Zhijian Zhao
  • Publication number: 20070155754
    Abstract: The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat obesity and other histamine H3 receptor-related diseases.
    Type: Application
    Filed: February 22, 2005
    Publication date: July 5, 2007
    Inventors: Lisa Beavers, Robert Gadski, Philip Hipskind, Cynthia Jesudason, Karen Lobb, Richard Pickard, Craig Lindsley
  • Publication number: 20070149536
    Abstract: The present invention is directed to compounds comprising a 2,3-diphenylquinoxaline moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
    Type: Application
    Filed: February 13, 2007
    Publication date: June 28, 2007
    Inventors: Craig Lindsley, Zhijian Zhao
  • Publication number: 20070142388
    Abstract: The present invention is directed to compounds comprising a 2,3-diphenylpyrazine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
    Type: Application
    Filed: February 8, 2007
    Publication date: June 21, 2007
    Inventors: Mark Duggan, Craig Lindsley, Zhijian Zhao
  • Publication number: 20070105902
    Abstract: The present invention is directed to compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.
    Type: Application
    Filed: November 10, 2004
    Publication date: May 10, 2007
    Inventors: Craig Lindsley, David Wisnoski, Zhijian Zhao